Condition: Heart Failure · Arrhythmia, Ventricular · Cardiomyopathy Ischemic · Sponsor: Heart and Diabetes Center North-Rhine Westfalia
CASTLE-VT is a randomized evaluation of prophylactic ablative treatment of arrhythmogenic ventricular scar in patients referred for HTx evaluation and diagnosed with ICM. Ablation will be performed with the use of a substrate-based approach in which the myocardial scar is mapped and ablated while the heart remains predominantly in sinus rhythm. The primary end point is the composite of all-cause mortality, worsening of HF requiring prioritized transplantation or LVAD implantation. The main secondary study end points are all-cause mortality, cardiovascular mortality, incidence of implantable cardioverter-defibrillator (ICD) therapy, hospitalizations, Quality of life, time to first ICD therapy, number of device-detected ventricular tachycardia/ventricular fibrillation episodes, LV function, and exercise tolerance. CASTLE-VT will randomize 160 patients with a follow up period of 2 years.
This description comes directly from the study's public registry record.
Christian Sohns, MD · 49 5731 971327 · csohns@hdz-nrw.de
Astrid Kleemeyer · 49 5731 971258 · akleemeyer@hdz-nrw.de
Always discuss trial participation with your own doctor first.
| Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW | Bad Oeynhausen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06556485